Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Shares Outstanding (Weighted Average) (2016 - 2025)

Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $19.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 5.73% year-over-year to $19.3 million; the TTM value through Dec 2025 reached $19.3 million, up 5.73%, while the annual FY2025 figure was $19.3 million, 5.73% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $19.3 million at Ligand Pharmaceuticals, roughly flat from $19.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $19.4 million in Q3 2025 and bottomed at $16.4 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $17.3 million (2023), against an average of $17.6 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) fell 0.57% in 2021 before it increased 8.23% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $16.6 million in 2021, then rose by 1.43% to $16.9 million in 2022, then grew by 2.55% to $17.3 million in 2023, then increased by 5.73% to $18.3 million in 2024, then grew by 5.73% to $19.3 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Shares Outstanding (Weighted Average) are $19.3 million (Q4 2025), $19.4 million (Q3 2025), and $19.3 million (Q2 2025).